{"filings":[{"id":90552,"accession_number":"0001493152-26-021329","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Pure Bioscience raises $1.0M in private placement at $0.0553/share; directors invest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 18,131,096 shares at $0.0553/share for $1.0M gross.","Director Tom Y. Lee invested ~$700,000; director Ivan Chen invested $27,650.","Net proceeds ~$1.0M for R&D, working capital, and general corporate purposes.","Shares sold to accredited investors under Section 4(a)(2)/Reg D exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100160,"accession_number":"0001493152-26-010383","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 revenue up 13% to $443K; net loss narrows; USDA cert for PURE Clean","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales Q2 $443K (up 13% YoY); six-month sales $1.15M (up 22% YoY).","Net loss Q2 $785K ($0.01/sh) vs $798K; six-month loss $1.249M vs $1.487M.","Received USDA Biobased Product Certification for new product PURE Clean; expects launch in fiscal Q3.","Partner Bonsai expanding online promotion; exploring biomedical space with Quip Labs; growth in transportation.","In-plant dairy trials at Cal Poly; new marketing campaign targeting dairy farmers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1150000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100159,"accession_number":"0001493152-26-007616","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience shareholders approve increase in authorized shares to 250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment increasing authorized common shares from 200M to 250M, with 63.87% of outstanding shares voting for.","Elected 7 directors, each receiving over 96% of votes cast.","Ratified Weinberg & Company as auditor for FY 2026 (99.81% approval).","Advisory vote on executive compensation passed with 96.68% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116497,"accession_number":"0001493152-25-027746","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports fiscal Q1 2026 revenue up 27% to $707K, net loss narrows to $464K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $707K for Q1 ended Oct 31, 2025, up 27% from $555K YoY.","Net loss $464K vs $689K year ago; net loss per share ($0.00) vs ($0.01).","Adjusted net loss (excl. share-based comp) was $430K vs $632K.","PURE Control now treating leafy greens for commercial sale; traction in transportation with SDC-powered sanitation.","Working with distribution partners in beverage and dairy to roll out membrane treatment solutions."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":707000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116496,"accession_number":"0001493152-25-024276","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"PURE Bioscience promotes Jeff Kitchell to President, Dolana Blount to VP of Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Kitchell appointed President and remains Corporate Secretary, effective Nov 17, 2025.","Robert Bartlett steps down as President but continues as CEO and board member.","Dolana Blount adds VP of Operations to her role as VP Regulatory Affairs.","Both Kitchell (24 yrs) and Blount (27 yrs) are internal promotions from within PURE.","No changes to compensation or other terms disclosed beyond standard officer indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116495,"accession_number":"0001493152-25-020058","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience FY2025 net product sales $2.2M, net loss narrows to $2.4M from $3.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $2,198K for FY2025, up 12.4% from $1,955K in FY2024.","Net loss improved to ($2.4M) from ($3.4M); loss per share ($0.02) vs ($0.03).","Net cash used in operations ($2.0M) vs ($2.5M) in prior year.","Expanded distribution with Hydrite Chemical; launched membrane treatment for dairy/beverage.","Excluding share-based compensation, net loss was ($2.3M) vs ($3.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149496,"accession_number":"0001641172-25-015242","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.","Net loss improved to $580K from $857K in same quarter last year.","Adjusted net loss (excl. share-based comp) was $547K vs $825K YoY.","EPS remained ($0.01) for both quarters; nine-month EPS ($0.02) vs ($0.03) last year.","CEO reports SDC dairy membrane solution now commercial at full-scale dairy plants."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1435000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168572,"accession_number":"0001493152-25-010568","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).","Net loss $798K vs $1,002K in prior-year quarter; loss per share unchanged at ($0.01).","SG&A expenses fell $194K due to reductions in personnel, professional fees, and stock comp.","Company advanced dairy membrane solutions to full-scale in-plant pilots with a large distribution partner.","Pilot data shows benefits in water/energy savings, fouling removal, and reduced downtime for dairy ops."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":946000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168571,"accession_number":"0001493152-25-003983","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience Announces Results of 2025 Annual Meeting of Stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all seven director nominees with approval ranging from 95.59% to 98.18%.","Ratified Weinberg & Company as independent auditor for fiscal year ending July 31, 2025, with 99.19% approval.","Approved executive compensation on a non-binding advisory basis with 95.49% of votes cast.","61,264,581 shares (54.77% of outstanding) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185682,"accession_number":"0001493152-24-050223","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.","Net loss narrowed to $689K from $735K YoY; net loss per share unchanged at ($0.01).","Excluding share-based compensation, net loss was $632K vs $655K YoY.","CEO cites unexpected interruption in product flow to a major customer and lack of replacement revenue as reasons for the decline."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":555000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185681,"accession_number":"0001493152-24-042926","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience reports FY 2024 net loss of $3.4M; product sales up 4.5% to $1.955M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $1.955M in FY 2024 vs $1.871M in FY 2023, up $84K (4.5%).","Net loss improved to ($3.4M) from ($3.9M); net loss per share ($0.03) vs ($0.04).","Net cash used in operations reduced to ($2.5M) from ($3.3M).","Shifted strategy to distribution model; partnered with multiple distributors in fiscal 2024.","R&D focused on Clean-in-Place solutions for food processing equipment sanitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202252,"accession_number":"0001493152-24-037627","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pure Bioscience secures up to $3M in convertible notes; initial $500k from director Tom Y. Lee","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial tranche of $500,000 convertible promissory note placed with director Tom Y. Lee (affiliates).","Notes bear 7.88% annual interest, mature 3 years; convertible into common at VWAP floor $0.095, cap $0.175.","Company may conduct subsequent closings up to $3.0 million aggregate principal through July 31, 2025.","Conversion triggers include automatic conversion one year after issuance at option of majority holders, and upon corporate transactions.","Offering is exempt from registration under Section 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202251,"accession_number":"0001493152-24-030966","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pure Bioscience increases authorized common shares from 150M to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved the amendment at the Feb 21, 2024 annual meeting.","Certificate of Amendment filed with Delaware on Aug 5, 2024, effective immediately.","Authorized common stock increased by 50 million shares (33% increase)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218338,"accession_number":"0001493152-24-023859","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q3 net product sales $440K, net loss $857K; loss per share ($0.01)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $440,000 for Q3 FY2024, up 8% vs $406,000 in prior-year quarter.","Net loss $857,000; narrower than $876,000 in Q3 FY2023; net loss per share unchanged ($0.01).","For the nine months ended April 30, 2024, net product sales $1,483,000, net loss $2,594,000.","Company transitioning to distributor model; new Tier Pricing Agreement developed for distributor margins.","Social media platform engagement up 167% in past 90 days; followers up nearly 70%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1483000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":218337,"accession_number":"0001493152-24-018114","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pure Bioscience appoints Darin Zehr to board of directors, effective May 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Darin Zehr appointed as independent director; will serve on Audit and Compensation Committees.","Zehr is General Manager of Commercial Food Sanitation LLC and has 22 years at Kraft Foods.","Annual cash retainer of $30,000 for board service, payable quarterly on a pro-rata basis.","No family relationships or material interests in transactions requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238273,"accession_number":"0001493152-24-011536","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Pure Bioscience raises $500K via convertible notes from director; up to $3M total","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.","Interest at 7.81% compounded annually; maturity 3 years from issuance.","Conversion price tied to 30-day VWAP, with floor $0.13 and cap $0.21 per share.","Subsequent closings allowed up to $3M aggregate principal through July 31, 2024.","Notes convertible at holder's or company's option; automatic conversion after one year if majority holders elect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238272,"accession_number":"0001493152-24-010300","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.","Q2 net loss per share ($0.01); six-month net product sales $1.043M, up 21% from $863K.","CEO cites unexpected interruption in product flow to one major customer as cause of revenue shortfall.","Company shifting from direct sales to distributor model to expand market coverage and accelerate growth.","New food segments and dairy/animal health show interest; registered to exhibit at IAFP July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":1043000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238271,"accession_number":"0001493152-24-007825","cik":1006028,"company_name":"PURE BIOSCIENCE, INC.","ticker":"PURE","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pure Bioscience shareholders approve increase in authorized shares to 200M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with 97-99% of votes cast; terms until next annual meeting.","Ratification of Weinberg & Company as auditor for FY ending July 31, 2024 approved (99.58%).","Non-binding advisory vote on executive compensation passed with 99.14% of votes cast.","2024 Equity Incentive Plan adopted with 99.17% of votes cast.","Amendment to increase authorized common stock from 150M to 200M shares approved with 55.13% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":10069783.15068493,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}